Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,22921184,maximum administered dose (MAD),MTD was not reached but the maximum administered dose (MAD) was 1110 mg/m(2).,Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22921184/),[mg] / [m(2],1110,119,DB00073,Rituximab
,16840188,overall response rate,"Best response included five CR, six PR, one SD and one PD with an overall response rate of 85% and complete response rate of 38%.","Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840188/),%,85,284,DB00073,Rituximab
,16840188,complete response rate,"Best response included five CR, six PR, one SD and one PD with an overall response rate of 85% and complete response rate of 38%.","Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840188/),%,38,285,DB00073,Rituximab
,15328168,serum half-life,The mean serum half-life was 23.9 days.,"Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15328168/),d,23.9,8738,DB00073,Rituximab
,15328168,time to progression,"Median duration of OR was 26.3 weeks, and median time to progression for responders was 35 weeks.","Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15328168/),weeks,35,8739,DB00073,Rituximab
,25111959,elimination half-life (t(1/2)),Bendamustine plasma concentration peaked near the end of infusion and was rapidly eliminated with a mean elimination half-life (t(1/2)) of 0.67-0.8 h.,Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25111959/),h,0.67-0.8,15648,DB00073,Rituximab
,25111959,overall response rate,"Of the evaluable patients (n = 14), the overall response rate was 78.6%, including 7.2% of patients having a complete response.",Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25111959/),%,78.6,15649,DB00073,Rituximab
,25111959,progression-free survival,Mean progression-free survival was 27.5 weeks.,Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25111959/),weeks,27.5,15650,DB00073,Rituximab
,10850396,elimination half-life,The Rituximab elimination half-life of approximately 20 days accounts for the demonstrated accumulation of MAb in serum samples.,Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850396/),d,20,19743,DB00073,Rituximab
,20225334,response rate,A previous study of intravenous (iv) bolus alemtuzumab plus rituximab in patients with chronic lymphocytic leukemia (CLL) recurrence produced a response rate of 54% after a 4-week treatment period.,Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20225334/),%,54,25943,DB00073,Rituximab
,20225334,overall response rate,"Seven patients (18%) achieved a complete response (CR), 4 (10%) a nodular partial response (nPR), and 10 (25%) a partial response for an overall response rate of 53%.",Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20225334/),%,53,25944,DB00073,Rituximab
,23295790,objective response rates,"Treatment at the MTD yielded objective response rates of 87%, 74%, and 20% for relapsed FL (n = 39), relapsed DLBCL (n = 42), and refractory aggressive NHL (n = 30), respectively.",Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23295790/),%,87,29365,DB00073,Rituximab
,23295790,objective response rates,"Treatment at the MTD yielded objective response rates of 87%, 74%, and 20% for relapsed FL (n = 39), relapsed DLBCL (n = 42), and refractory aggressive NHL (n = 30), respectively.",Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23295790/),%,74,29366,DB00073,Rituximab
,23295790,objective response rates,"Treatment at the MTD yielded objective response rates of 87%, 74%, and 20% for relapsed FL (n = 39), relapsed DLBCL (n = 42), and refractory aggressive NHL (n = 30), respectively.",Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23295790/),%,20,29367,DB00073,Rituximab
,23295790,progression-free survival (PFS) rate,"The 2-year progression-free survival (PFS) rate was 68% (median, not reached) for FL and 42% (median, 17.1 months) for relapsed DLBCL.",Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23295790/),%,68,29368,DB00073,Rituximab
,23295790,progression-free survival (PFS) rate,"The 2-year progression-free survival (PFS) rate was 68% (median, not reached) for FL and 42% (median, 17.1 months) for relapsed DLBCL.",Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23295790/),%,42,29369,DB00073,Rituximab
,34080039,area under the concentration-time curve [AUC] ratio,"Extrapolation of the vincristine mechanistic PBPK model to other P-gp substrates further suggested DDI risk when ibrutinib (area under the concentration-time curve [AUC] ratio: 1.8), but not acalabrutinib (AUC ratio: 0.92), was given orally with venetoclax or digoxin.",Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34080039/),,1.8,41785,DB00073,Rituximab
,34080039,AUC ratio,"Extrapolation of the vincristine mechanistic PBPK model to other P-gp substrates further suggested DDI risk when ibrutinib (area under the concentration-time curve [AUC] ratio: 1.8), but not acalabrutinib (AUC ratio: 0.92), was given orally with venetoclax or digoxin.",Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34080039/),,0.92,41786,DB00073,Rituximab
,22223529,progression-free survival,A partial or complete response was observed in 5 of 23 (22%) patients and the median progression-free survival was 25.4 weeks.,"Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22223529/),weeks,25.4,47536,DB00073,Rituximab
,20491780,maximum tolerated dose,"No patient had dose-limiting toxicities, and the maximum tolerated dose, previously determined in non-Japanese patients (1.8 mg/m(2)), was confirmed.",Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20491780/),mg,1,55478,DB00073,Rituximab
,20491780,overall response rate,The overall response rate was 85% (11/13).,Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20491780/),%,85,55479,DB00073,Rituximab
,29362903,volume of distribution of the central compartment (V1),"The volume of distribution of the central compartment (V1) and clearance of RXTM83 were estimated at 3.19 L and 12.5 mL/h, respectively.","Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29362903/),l,3.19,59960,DB00073,Rituximab
,29362903,clearance,"The volume of distribution of the central compartment (V1) and clearance of RXTM83 were estimated at 3.19 L and 12.5 mL/h, respectively.","Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29362903/),[ml] / [h],12.5,59961,DB00073,Rituximab
,15657402,overall response rate (ORR),The overall response rate (ORR) for the entire group was 59% with 27% complete responses (CRs) and 32% partial responses.,Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657402/),%,59,61531,DB00073,Rituximab
,15657402,PFS,"The median PFS for all patients was 19 months, with a median follow-up of 25 months.",Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657402/),month,19,61532,DB00073,Rituximab
,15657402,time to repeat bolus,"The median time to repeat bolus was 5 months (range, 1 to 9 months) for the first, 3.5 months (range, 2 to 5 months) for the second, and 3 months (range, 2 to 4 months) for the third infusion.",Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657402/),month,5,61533,DB00073,Rituximab
,15657402,time to repeat bolus,"The median time to repeat bolus was 5 months (range, 1 to 9 months) for the first, 3.5 months (range, 2 to 5 months) for the second, and 3 months (range, 2 to 4 months) for the third infusion.",Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657402/),month,3.5,61534,DB00073,Rituximab
,15657402,time to repeat bolus,"The median time to repeat bolus was 5 months (range, 1 to 9 months) for the first, 3.5 months (range, 2 to 5 months) for the second, and 3 months (range, 2 to 4 months) for the third infusion.",Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657402/),month,3,61535,DB00073,Rituximab
,24134141,Activity clearance,Activity clearance from whole body of 88.7 hours measured by imaging 131I-rituximab was significantly slower (p<0.001) than the mean effective half-life clearance of 60.8 hours calculated from the sampling peripheral blood.,Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134141/),h,88.7,61698,DB00073,Rituximab
,24134141,effective half-life clearance,Activity clearance from whole body of 88.7 hours measured by imaging 131I-rituximab was significantly slower (p<0.001) than the mean effective half-life clearance of 60.8 hours calculated from the sampling peripheral blood.,Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134141/),h,60.8,61699,DB00073,Rituximab
,24134141,absorbed self-dose,"The absorbed self-dose in red marrow, measured using imaging, was 1.02 Gy compared with the dose (0.81 Gy) calculated from blood sampling.",Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134141/),gy,1.02,61700,DB00073,Rituximab
,22431570,overall response,"The best overall response was 43%, with 5 complete responses and 4 partial responses.",Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22431570/),%,43,66406,DB00073,Rituximab
,28239897,specific clearance,"The data were best described by a two-compartment model comprising linear nonspecific clearance of 0.252 [95% confidence interval (CI): 0.227-0.279] l day-1 and time-varying specific clearance of 0.278 (95% CI: 0.181-0.390) l day-1 , corresponding to target-mediated drug disposition of rituximab.",Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28239897/),[l] / [d],0.278,68234,DB00073,Rituximab
,28239897,Rate constant of specific clearance decay,"Rate constant of specific clearance decay was 0.143 day-1 (95% CI: 0.0478-0.418) in patients with no disease progression, while in patients with disease progression it was 82.2% lower (95% CI: 33.4-95.0).",Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28239897/),1/[d],0.143,68235,DB00073,Rituximab
,24717109,Progression-free survivial (PFS),Investigator-assessed median Progression-free survivial (PFS) was 38.3 weeks.,"Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24717109/),weeks,38.3,73259,DB00073,Rituximab
,25829094,t 1/2,"Subsequent elimination is triphasic, with the intermediate t 1/2 (~40 min) as the effective t 1/2 since the final phase represents <1 % of the area under the curve.",Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25829094/),min,40,86615,DB00073,Rituximab
,32737470,minimum optimal C1-trough,"The first cycle trough concentration (C1-trough) of rituximab was a significant independent risk factor for achieving CR in matched-pair logistic regression analysis, rather than the concentrations in later cycles; the recommendatory minimum optimal C1-trough was 13.60 μg/mL.",Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737470/),[μg] / [ml],13.60,88213,DB00073,Rituximab
,32737470,C1-trough,"Patients with grade 1/2 had significantly lower C1-trough compared with grade 3 (12.21 μg/mL vs. 23.45 μg/mL, P < 0.001), only 30% patients with grade 1/2 could reach 13.60 μg/mL, compared with 91.67% in patients with grade 3, which was in accord with its unsatisfactory CR rates (43.33% vs. 76.32%).",Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737470/),[μg] / [ml],12.21,88214,DB00073,Rituximab
,32737470,C1-trough,"Patients with grade 1/2 had significantly lower C1-trough compared with grade 3 (12.21 μg/mL vs. 23.45 μg/mL, P < 0.001), only 30% patients with grade 1/2 could reach 13.60 μg/mL, compared with 91.67% in patients with grade 3, which was in accord with its unsatisfactory CR rates (43.33% vs. 76.32%).",Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737470/),[μg] / [ml],23.45,88215,DB00073,Rituximab
,12621016,radiation absorbed doses,"Median radiation absorbed doses for (90)Y were 7.42 Gy to spleen, 4.50 Gy to liver, 2.11 Gy to lung, 0.23 Gy to kidney, 0.62 Gy (blood-derived method) and 0.97 Gy (sacral image-derived method) to red marrow, and 0.57 Gy to total body.",Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621016/),g,7.42,88975,DB00073,Rituximab
,12621016,radiation absorbed doses,"Median radiation absorbed doses for (90)Y were 7.42 Gy to spleen, 4.50 Gy to liver, 2.11 Gy to lung, 0.23 Gy to kidney, 0.62 Gy (blood-derived method) and 0.97 Gy (sacral image-derived method) to red marrow, and 0.57 Gy to total body.",Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621016/),,4.50,88976,DB00073,Rituximab
,12621016,radiation absorbed doses,"Median radiation absorbed doses for (90)Y were 7.42 Gy to spleen, 4.50 Gy to liver, 2.11 Gy to lung, 0.23 Gy to kidney, 0.62 Gy (blood-derived method) and 0.97 Gy (sacral image-derived method) to red marrow, and 0.57 Gy to total body.",Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621016/),,2,88977,DB00073,Rituximab
,12621016,radiation absorbed doses,"Median radiation absorbed doses for (90)Y were 7.42 Gy to spleen, 4.50 Gy to liver, 2.11 Gy to lung, 0.23 Gy to kidney, 0.62 Gy (blood-derived method) and 0.97 Gy (sacral image-derived method) to red marrow, and 0.57 Gy to total body.",Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621016/),,0,88978,DB00073,Rituximab
,12621016,radiation absorbed doses,"Median radiation absorbed doses for (90)Y were 7.42 Gy to spleen, 4.50 Gy to liver, 2.11 Gy to lung, 0.23 Gy to kidney, 0.62 Gy (blood-derived method) and 0.97 Gy (sacral image-derived method) to red marrow, and 0.57 Gy to total body.",Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621016/),g,0.62,88979,DB00073,Rituximab
,12621016,radiation absorbed doses,"Median radiation absorbed doses for (90)Y were 7.42 Gy to spleen, 4.50 Gy to liver, 2.11 Gy to lung, 0.23 Gy to kidney, 0.62 Gy (blood-derived method) and 0.97 Gy (sacral image-derived method) to red marrow, and 0.57 Gy to total body.",Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621016/),g,0.97,88980,DB00073,Rituximab
,12621016,effective blood half-life,"The median effective blood half-life was 27 h, and the area under the curve (AUC) was 25 h.",Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621016/),h,27,88981,DB00073,Rituximab
,12621016,area under the curve (AUC),"The median effective blood half-life was 27 h, and the area under the curve (AUC) was 25 h.",Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621016/),h,25,88982,DB00073,Rituximab
,24927856,half-life,"In the 10 and 20 mg/kg dose cohorts, the mean half-life was 8 and 10 days following the first dose, and 12 or 14 days following 12 doses of otlertuzumab, respectively.","Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24927856/),d,8,91278,DB00073,Rituximab
,24927856,half-life,"In the 10 and 20 mg/kg dose cohorts, the mean half-life was 8 and 10 days following the first dose, and 12 or 14 days following 12 doses of otlertuzumab, respectively.","Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24927856/),d,10,91279,DB00073,Rituximab
,24927856,half-life,"In the 10 and 20 mg/kg dose cohorts, the mean half-life was 8 and 10 days following the first dose, and 12 or 14 days following 12 doses of otlertuzumab, respectively.","Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24927856/),d,12,91280,DB00073,Rituximab
,24927856,half-life,"In the 10 and 20 mg/kg dose cohorts, the mean half-life was 8 and 10 days following the first dose, and 12 or 14 days following 12 doses of otlertuzumab, respectively.","Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24927856/),d,14,91281,DB00073,Rituximab
,24927856,Overall response rate,Overall response rate was 83% (10/12) with 4 CRs (32%).,"Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24927856/),%,83,91282,DB00073,Rituximab
,31097627,half-life,Peak concentrations and systemic exposure of olaptesed pegol were dose-linear; plasma elimination was monophasic with a 53.2 h half-life.,Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31097627/),h,53.2,92480,DB00073,Rituximab
,31097627,overall response rate,"The combination regimen yielded an overall response rate of 86%, with 11% of patients achieving a complete response and 75% a partial response.",Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31097627/),%,86,92481,DB00073,Rituximab
,31097627,progression-free survival,"The median progression-free survival was 15.4 (95% confidence interval: 12.2, 26.2) months while the median overall survival was not reached with >80% of patients alive after a median follow-up of 28 months.",Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31097627/),month,15.4,92482,DB00073,Rituximab
,25403207,complete response (CR)/unconfirmed CR rate,"The complete response (CR)/unconfirmed CR rate was 85% in 189 evaluable patients, 90% for 90 good-prognosis patients (International Prognostic Index [IPI], 1 or 2), and 81% for 99 poor-prognosis patients (IPI, 3 to 5); 3-year event-free survival (EFS) was 71%, 75%, and 67%, respectively; and 3-year overall survival (OS) was 84%, 88%, and 80%, respectively, with no differences between men and women.",Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403207/),%,85,99063,DB00073,Rituximab
,25403207,complete response (CR)/unconfirmed CR rate,"The complete response (CR)/unconfirmed CR rate was 85% in 189 evaluable patients, 90% for 90 good-prognosis patients (International Prognostic Index [IPI], 1 or 2), and 81% for 99 poor-prognosis patients (IPI, 3 to 5); 3-year event-free survival (EFS) was 71%, 75%, and 67%, respectively; and 3-year overall survival (OS) was 84%, 88%, and 80%, respectively, with no differences between men and women.",Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403207/),%,90,99064,DB00073,Rituximab
,25403207,complete response (CR)/unconfirmed CR rate,"The complete response (CR)/unconfirmed CR rate was 85% in 189 evaluable patients, 90% for 90 good-prognosis patients (International Prognostic Index [IPI], 1 or 2), and 81% for 99 poor-prognosis patients (IPI, 3 to 5); 3-year event-free survival (EFS) was 71%, 75%, and 67%, respectively; and 3-year overall survival (OS) was 84%, 88%, and 80%, respectively, with no differences between men and women.",Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403207/),%,81,99065,DB00073,Rituximab
,28220479,overall response rate,"The overall response rate for evaluable patients (n = 31) was 45% (13% complete responses, 32% partial responses).","A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28220479/),%,45,101088,DB00073,Rituximab
,28220479,duration of response,"Median duration of response and progression-free survival were 9·2 months and 7·7 months, respectively.","A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28220479/),month,9·2,101089,DB00073,Rituximab
,28220479,progression-free survival,"Median duration of response and progression-free survival were 9·2 months and 7·7 months, respectively.","A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28220479/),month,7·7,101090,DB00073,Rituximab
less,26054711,serum half-life,The serum half-life of RTX in this patient was less than 1 day compared to 20 days in patients without protein losses.,Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26054711/),d,1,101191,DB00073,Rituximab
,26054711,serum half-life,The serum half-life of RTX in this patient was less than 1 day compared to 20 days in patients without protein losses.,Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26054711/),d,20,101192,DB00073,Rituximab
,17766699,terminal half-life,The mean terminal half-life of rituximab was 19 to 22 days; pharmacokinetic parameters were similar whether rituximab was administered alone or with methotrexate or cyclophosphamide.,Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17766699/),d,19 to 22,102044,DB00073,Rituximab
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],299,110190,DB00073,Rituximab
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],384,110191,DB00073,Rituximab
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],245,110192,DB00073,Rituximab
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],321,110193,DB00073,Rituximab
,23802659,troughs,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),d,26-29,110194,DB00073,Rituximab
,23802659,t½,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),d,26-29,110195,DB00073,Rituximab
,21887597,bioavailability,"For the 1 mg/kg dose, bioavailability was approximately 70% at all tested injection sites, with faster absorption from the foot (T(max) = 12 h for foot vs. 4.6 days for back).","Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21887597/),%,70,113165,DB00073,Rituximab
,21887597,T(max),"For the 1 mg/kg dose, bioavailability was approximately 70% at all tested injection sites, with faster absorption from the foot (T(max) = 12 h for foot vs. 4.6 days for back).","Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21887597/),h,12,113166,DB00073,Rituximab
,21887597,T(max),"For the 1 mg/kg dose, bioavailability was approximately 70% at all tested injection sites, with faster absorption from the foot (T(max) = 12 h for foot vs. 4.6 days for back).","Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21887597/),d,4.6,113167,DB00073,Rituximab
,21887597,Bioavailability,Bioavailability for the 10 mg/kg dose was 44 and 31% for the abdomen and back sites and 18% for 40 mg/kg injected at the back.,"Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21887597/),%,44,113168,DB00073,Rituximab
,21887597,Bioavailability,Bioavailability for the 10 mg/kg dose was 44 and 31% for the abdomen and back sites and 18% for 40 mg/kg injected at the back.,"Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21887597/),%,31,113169,DB00073,Rituximab
,21887597,Bioavailability,Bioavailability for the 10 mg/kg dose was 44 and 31% for the abdomen and back sites and 18% for 40 mg/kg injected at the back.,"Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21887597/),%,18,113170,DB00073,Rituximab
,19432900,overall response rate,"The overall response rate was 50% (9/18; 80% confidence interval, 35-65%), with 11% (2/18) complete response.",Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19432900/),%,50,115476,DB00073,Rituximab
,19432900,time to progression,"With a median follow-up of 296 days, the estimated median time to progression for 18 eligible patients was 382 days.",Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19432900/),d,382,115477,DB00073,Rituximab
,23046388,end-of-treatment response rate,"Out of 12 patients, 7 responded (end-of-treatment response rate 58%), with 2 complete responses and 5 partial responses.",Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23046388/),%,58,117394,DB00073,Rituximab
,15111353,PFS,"Median PFS of 53 evaluable patients was 52 days, whereas time to progression of 21 eligible responders was 245 days.",Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15111353/),d,52,120121,DB00073,Rituximab
,15111353,time to progression,"Median PFS of 53 evaluable patients was 52 days, whereas time to progression of 21 eligible responders was 245 days.",Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15111353/),d,245,120122,DB00073,Rituximab
<,20175870,CD19,All patients achieved CD19 < 1%.,Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175870/),%,1,121053,DB00073,Rituximab
,20175870,time to undetectable rituximab,"In group 1, the median time to undetectable rituximab was 5 months (range 0-12 months) and to B cell return was 7 months (range 3-24 months).",Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175870/),month,5,121054,DB00073,Rituximab
,27447545,CL),"Population estimates for parent drug (CL) and metabolite (CLm ) clearance were 62 l h-1 and 27 l h-1 , respectively.",Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27447545/),[l] / [h],62,121257,DB00073,Rituximab
,27447545,clearance,"Population estimates for parent drug (CL) and metabolite (CLm ) clearance were 62 l h-1 and 27 l h-1 , respectively.",Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27447545/),[l] / [h],27,121258,DB00073,Rituximab
,27447545,fraction metabolized to DOXol (Fm ),The fraction metabolized to DOXol (Fm ) was estimated at 0.22.,Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27447545/),,0.22,121259,DB00073,Rituximab
,31454097,Elimination half-life,Elimination half-life of rituximab was 18 days.,CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31454097/),d,18,124689,DB00073,Rituximab
,31454097,DAS28,"At 6 months, a deeper DAS28 decrease was observed in patients when CD4+ cell count is decreased: median [interquartile range] of DAS28 was 3.7 [2.9-4.4] and 4.5 [3.7-5.3] in patients with and without CD4+ decrease, respectively.",CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31454097/),,3.7,124690,DB00073,Rituximab
,31454097,DAS28,"At 6 months, a deeper DAS28 decrease was observed in patients when CD4+ cell count is decreased: median [interquartile range] of DAS28 was 3.7 [2.9-4.4] and 4.5 [3.7-5.3] in patients with and without CD4+ decrease, respectively.",CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31454097/),,4.5,124691,DB00073,Rituximab
,9336364,serum half-life (,"Antibody serum half-life (and maximum concentration [Cmax]) generally increased between the first and fourth infusions (33.2 hours v 76.6 hours, respectively) following the 375-mg/m2 doses.",IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9336364/),h,33.2,129932,DB00073,Rituximab
,9336364,maximum concentration [Cmax],"Antibody serum half-life (and maximum concentration [Cmax]) generally increased between the first and fourth infusions (33.2 hours v 76.6 hours, respectively) following the 375-mg/m2 doses.",IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9336364/),h,76.6,129933,DB00073,Rituximab
,9336364,time to disease progression,"Six of 18 assessable patients had a partial remission (PR), with a median time to disease progression of 6.4 months (range, 3 to 21.7).",IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9336364/),month,6.4,129934,DB00073,Rituximab
,11304767,overall response rate,"The overall response rate was 45% (3% CR, 42% PR; 95% CI 28% to 64%).",Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304767/),%,45,131751,DB00073,Rituximab
,11304767,response duration,"Median response duration for these 15 patients was 10 months (95% CI, 6.8-13.2; range, 3 to 17+).",Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304767/),month,10,131752,DB00073,Rituximab
,23645694,overall response rate,"The overall response rate by National Cancer Institute-Working Group criteria was 61%, and the rate of complete bone marrow response was 43%, most of whom were negative for minimal residual disease.",A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23645694/),%,61,132278,DB00073,Rituximab
,23645694,rate of complete bone marrow response,"The overall response rate by National Cancer Institute-Working Group criteria was 61%, and the rate of complete bone marrow response was 43%, most of whom were negative for minimal residual disease.",A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23645694/),%,43,132279,DB00073,Rituximab
,23645694,overall survival,"Median overall survival was 35 months, with 12 patients able to proceed to stem cell transplantation.",A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23645694/),month,35,132280,DB00073,Rituximab
,21558622,biological half-life,The calculated biological half-life of ¹³¹I-rituximab was 684 hrs.,The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21558622/),h,684,141234,DB00073,Rituximab
,21558622,half-life,This biological half-life corresponded well with the half-life of unlabeled rituximab which was approximately 720 hrs.,The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21558622/),h,720,141235,DB00073,Rituximab
,9818074,response duration,"The median response duration and time to progression are 11.6 and 13.2 months, respectively.",Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818074/),month,11.6,146564,DB00073,Rituximab
,9818074,time to progression,"The median response duration and time to progression are 11.6 and 13.2 months, respectively.",Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818074/),month,13.2,146565,DB00073,Rituximab
,9818074,half-life,The half-life of the monoclonal antibody increased from 76.3 hours after the first infusion to 205.8 hours after the fourth infusion and was concomitant with a four-fold decrease in the antibody clearance.,Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818074/),h,76.3,146566,DB00073,Rituximab
,9818074,half-life,The half-life of the monoclonal antibody increased from 76.3 hours after the first infusion to 205.8 hours after the fourth infusion and was concomitant with a four-fold decrease in the antibody clearance.,Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818074/),h,205.8,146567,DB00073,Rituximab
,9818074,serum levels,"At three months and six months post-treatment, the median Rituximab serum levels were 20.3 micrograms/ml (range 0.0 to 96.8 micrograms/ml in 104 patients) and 1.3 micrograms/ml (range 0.0-28.7 micrograms/ml in 13 patients), respectively.",Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818074/),[μg] / [ml],20.3,146568,DB00073,Rituximab
,9818074,serum levels,"At three months and six months post-treatment, the median Rituximab serum levels were 20.3 micrograms/ml (range 0.0 to 96.8 micrograms/ml in 104 patients) and 1.3 micrograms/ml (range 0.0-28.7 micrograms/ml in 13 patients), respectively.",Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818074/),[μg] / [ml],1.3,146569,DB00073,Rituximab
,32963641,tmax,Plasma concentrations of rHuPH20 increased during the 5-minute intravenous infusion (median tmax = 6 minutes from intravenous initiation) followed by a rapid plasma clearance (t1/2 ∼10 minutes from intravenous initiation).,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32963641/),min,6,147448,DB00073,Rituximab
,32963641,tmax,Plasma hyaluronan concentrations increased with dose and time (tmax range = 45‒120 minutes from intravenous initiation) and returned to baseline within 1 week of administration.,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32963641/),min,45‒120,147449,DB00073,Rituximab
,33942442,Overall response rate,"Overall response rate was 42.9% at EOT, and median progression-free survival was 5.2 months (95% CI 3.6-not evaluable).",A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33942442/),%,42.9,148227,DB00073,Rituximab
,33942442,progression-free survival,"Overall response rate was 42.9% at EOT, and median progression-free survival was 5.2 months (95% CI 3.6-not evaluable).",A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33942442/),month,5.2,148228,DB00073,Rituximab
more,34219092,serum half-life,"The pharmacokinetics of rituximab differs substantially among individuals and its serum half-life is approximately more than 500 hours; therefore, the peak concentration increases cumulatively by weekly infusion.",[Optimization of rituximab dosing schedule in R-CHOP therapy for diffuse large B-cell lymphoma]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34219092/),h,500,148482,DB00073,Rituximab
,31026092,elimination rate constant,The elimination rate constant (% relative standard error) of rituximab effect decay was 0.036 (22.7%) days-1 and CD19+ turnover was 0.02 (41%) days-1 corresponding to half-lives of 19 and 35 days respectively.,Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31026092/),1/[d],0.036,153268,DB00073,Rituximab
,31026092,turnover,The elimination rate constant (% relative standard error) of rituximab effect decay was 0.036 (22.7%) days-1 and CD19+ turnover was 0.02 (41%) days-1 corresponding to half-lives of 19 and 35 days respectively.,Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31026092/),%,0.02,153269,DB00073,Rituximab
,31026092,half-lives,The elimination rate constant (% relative standard error) of rituximab effect decay was 0.036 (22.7%) days-1 and CD19+ turnover was 0.02 (41%) days-1 corresponding to half-lives of 19 and 35 days respectively.,Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31026092/),d,19,153270,DB00073,Rituximab
,31026092,half-lives,The elimination rate constant (% relative standard error) of rituximab effect decay was 0.036 (22.7%) days-1 and CD19+ turnover was 0.02 (41%) days-1 corresponding to half-lives of 19 and 35 days respectively.,Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31026092/),d,35,153271,DB00073,Rituximab
,22753910,MTD,The MTD was 160 mg/m(2) once every 21 days.,Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753910/),[mg] / [m],160,155879,DB00073,Rituximab
,22753910,clearance,"The pharmacokinetic profile of SAR3419 is characterized by linear kinetics, low clearance from 0.2 to 0.6 L/d/m(2), and an elimination half-life in the range of 3 to 7 days.",Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753910/),[d·l] / [m(2],0.2,155880,DB00073,Rituximab
,22753910,elimination half-life,"The pharmacokinetic profile of SAR3419 is characterized by linear kinetics, low clearance from 0.2 to 0.6 L/d/m(2), and an elimination half-life in the range of 3 to 7 days.",Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753910/),d,3 to 7,155881,DB00073,Rituximab
,22753910,MTD,"Using an every 3-week-schedule of SAR3419 for six cycles, the MTD is 160 mg/m(2).",Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753910/),[mg] / [m],160,155882,DB00073,Rituximab
,15824926,Effective radiation dose,Effective radiation dose calculated from attenuation-corrected WB scans and blood using Mirdose3.1 was 0.53+0.05 mSv/MBq (range 0.48-0.59 mSv/MBq).,Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15824926/),[msv] / [Mbq],0.53,157964,DB00073,Rituximab
,25942994,maximum tolerated dose,The maximum tolerated dose for navitoclax in combination was 250 mg/d.,"Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25942994/),,250,159520,DB00073,Rituximab
,25942994,response rate,"The response rate in patients with follicular lymphoma was 9/12, including five complete responses.","Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25942994/),-1,9,159521,DB00073,Rituximab
,30689002,CL,"The population PK parameters for CP were: CL = 3.58 L/h, Vmale = 32.2 L, and Vfemale = 28.7 L.",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),[l] / [h],3.58,161752,DB00073,Rituximab
,30689002,Vmale,"The population PK parameters for CP were: CL = 3.58 L/h, Vmale = 32.2 L, and Vfemale = 28.7 L.",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,32.2,161753,DB00073,Rituximab
,30689002,Vfemale,"The population PK parameters for CP were: CL = 3.58 L/h, Vmale = 32.2 L, and Vfemale = 28.7 L.",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,28.7,161754,DB00073,Rituximab
,30689002,CL,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),[l] / [h],51.1,161755,DB00073,Rituximab
,30689002,Q,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),[l] / [h],49.6,161756,DB00073,Rituximab
,30689002,V1,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,29.4,161757,DB00073,Rituximab
,30689002,V2,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,"1,130",161758,DB00073,Rituximab
,30689002,V1,VCR increases DOXO V1 from 29.4 L to 57.5 L (p = 0.02).,Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,29.4,161759,DB00073,Rituximab
,30689002,V1,VCR increases DOXO V1 from 29.4 L to 57.5 L (p = 0.02).,Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,57.5,161760,DB00073,Rituximab
,32222808,volume of distribution,"Geometric mean volume of distribution and clearance of acMMAE ranged from 57.3 to 95.6 mL/kg and 12.7 to 18.2 mL/kg/day, respectively.",Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222808/),[ml] / [kg],57.3 to 95.6,163246,DB00073,Rituximab
,32222808,clearance,"Geometric mean volume of distribution and clearance of acMMAE ranged from 57.3 to 95.6 mL/kg and 12.7 to 18.2 mL/kg/day, respectively.",Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222808/),[ml] / [d·kg],12.7 to 18.2,163247,DB00073,Rituximab
,32222808,elimination half-life,acMMAE exhibited multi-exponential decay (elimination half-life ~ 1 week).,Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222808/),week,1,163248,DB00073,Rituximab
,12804042,radiation absorbed doses,"Median radiation absorbed doses were 48 cGy to red marrow (range: 6.5-95 cGy), 393 cGy to liver (range: 92-1581 cGy), 522 cGy to spleen (range: 165-1711 cGy), 162 cGy to lungs (41-295 cGy), and 14 cGy to kidneys (0.03-65 cGy).",Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12804042/),cgy,48,170124,DB00073,Rituximab
,12804042,radiation absorbed doses,"Median radiation absorbed doses were 48 cGy to red marrow (range: 6.5-95 cGy), 393 cGy to liver (range: 92-1581 cGy), 522 cGy to spleen (range: 165-1711 cGy), 162 cGy to lungs (41-295 cGy), and 14 cGy to kidneys (0.03-65 cGy).",Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12804042/),cg,393,170125,DB00073,Rituximab
,12804042,radiation absorbed doses,"Median radiation absorbed doses were 48 cGy to red marrow (range: 6.5-95 cGy), 393 cGy to liver (range: 92-1581 cGy), 522 cGy to spleen (range: 165-1711 cGy), 162 cGy to lungs (41-295 cGy), and 14 cGy to kidneys (0.03-65 cGy).",Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12804042/),cgy,522,170126,DB00073,Rituximab
,12804042,radiation absorbed doses,"Median radiation absorbed doses were 48 cGy to red marrow (range: 6.5-95 cGy), 393 cGy to liver (range: 92-1581 cGy), 522 cGy to spleen (range: 165-1711 cGy), 162 cGy to lungs (41-295 cGy), and 14 cGy to kidneys (0.03-65 cGy).",Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12804042/),cgy,162,170127,DB00073,Rituximab
,12804042,radiation absorbed doses,"Median radiation absorbed doses were 48 cGy to red marrow (range: 6.5-95 cGy), 393 cGy to liver (range: 92-1581 cGy), 522 cGy to spleen (range: 165-1711 cGy), 162 cGy to lungs (41-295 cGy), and 14 cGy to kidneys (0.03-65 cGy).",Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12804042/),cgy,14,170128,DB00073,Rituximab
,26947201,trough serum concentration,"At cycle five, the geometric mean trough serum concentration in patients given subcutaneous rituximab was non-inferior to that in patients given intravenous rituximab (97·5 μg/mL vs 61·5 μg/mL), with an adjusted geometric mean ratio of 1·53 (90% CI 1·27-1·85).","Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26947201/),[μg] / [ml],97·5,171354,DB00073,Rituximab
,26947201,trough serum concentration,"At cycle five, the geometric mean trough serum concentration in patients given subcutaneous rituximab was non-inferior to that in patients given intravenous rituximab (97·5 μg/mL vs 61·5 μg/mL), with an adjusted geometric mean ratio of 1·53 (90% CI 1·27-1·85).","Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26947201/),[μg] / [ml],61·5,171355,DB00073,Rituximab
,30060083,overall response rate,"For all patients, overall response rate was 65%.","Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30060083/),%,65,178091,DB00073,Rituximab
,30060083,overall response,"Median duration of overall response, overall survival, and progression-free survival was 38.3 months [95% confidence interval (CI) 10.4-NR], not yet reached, and 10.7 months (95% CI 4.3-21.0), respectively.","Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30060083/),month,38.,178092,DB00073,Rituximab
,30060083,progression-free survival,"Median duration of overall response, overall survival, and progression-free survival was 38.3 months [95% confidence interval (CI) 10.4-NR], not yet reached, and 10.7 months (95% CI 4.3-21.0), respectively.","Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30060083/),,10,178093,DB00073,Rituximab
,20157180,objective response rate,The objective response rate was 38% and was similar in patients with low-affinity and high-affinity variants of the Fcgamma receptor IIIa (FcgammaRIIIa).,"Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20157180/),%,38,186013,DB00073,Rituximab
,20157180,progression-free survival,"With follow-up of approximately 28 months, the median progression-free survival was 11.4 months.","Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20157180/),month,11.4,186014,DB00073,Rituximab
,31586310,non-specific clearance,The mean (inter-individual standard deviation) estimated non-specific clearance was 0.15 L/day (0.30%) and the target-mediated elimination rate constant was 2.4 × 10-5 nmol/day.,Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31586310/),[l] / [d],0.15,190984,DB00073,Rituximab
,31586310,target-mediated elimination rate constant,The mean (inter-individual standard deviation) estimated non-specific clearance was 0.15 L/day (0.30%) and the target-mediated elimination rate constant was 2.4 × 10-5 nmol/day.,Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31586310/),[nM] / [d],2.4 × 10-5,190985,DB00073,Rituximab
,31586310,elimination half-lives,"The elimination half-lives for MPO-ANCA and PR3-ANCA were 24 and 18 days, respectively.",Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31586310/),d,24,190986,DB00073,Rituximab
,31586310,elimination half-lives,"The elimination half-lives for MPO-ANCA and PR3-ANCA were 24 and 18 days, respectively.",Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31586310/),d,18,190987,DB00073,Rituximab
,25394095,concentration,Plasma concentrations of raltegravir in eight patients showed a median concentration of 143 ng/mL (79-455).,"Efficacy, safety, and lack of interactions with the use of raltegravir in HIV-infected patients undergoing antineoplastic chemotherapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25394095/),[ng] / [ml],143,195476,DB00073,Rituximab
≥,28251914,AUC,"A high AUC in cycle 1 (≥9400 mg × h per liter) was associated with better response (odds ratio, 5.56; P = .0006) and longer PFS (hazard ratio [HR], 0.38; P = .011) and OS (HR, 0.17; P = .001).",Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28251914/),[h·mg] / [l],9400,197616,DB00073,Rituximab
,25377184,Bioavailability,"Bioavailability, as estimated by our pharmacokinetic model, increased from 29% in isotonic buffer to 54% in hypertonic buffer containing NaCl, to almost complete bioavailability in hypertonic buffers containing high dose OPLS or mannitol.","Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377184/),%,29,199098,DB00073,Rituximab
,25377184,Bioavailability,"Bioavailability, as estimated by our pharmacokinetic model, increased from 29% in isotonic buffer to 54% in hypertonic buffer containing NaCl, to almost complete bioavailability in hypertonic buffers containing high dose OPLS or mannitol.","Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377184/),%,54,199099,DB00073,Rituximab
,27329361,volume of distribution of central compartment,"The volume of distribution of central compartment and clearance of Reditux™ were estimated at 0.95 L and 5.98 mL/h, respectively.","Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27329361/),l,0.95,200467,DB00073,Rituximab
,27329361,clearance of Reditux™,"The volume of distribution of central compartment and clearance of Reditux™ were estimated at 0.95 L and 5.98 mL/h, respectively.","Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27329361/),[ml] / [h],5.98,200468,DB00073,Rituximab
,27154915,overall response rate (ORR),"Among patients receiving the MTD (n = 38), the overall response rate (ORR) was 84% (n = 32), including 24% (n = 9) with complete response; the ORR was 100% for patients with indolent lymphoma (n = 27) and 57% for those with aggressive histology lymphoma (n = 21).",Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154915/),%,84,202921,DB00073,Rituximab
,27154915,overall response rate (ORR),"Among patients receiving the MTD (n = 38), the overall response rate (ORR) was 84% (n = 32), including 24% (n = 9) with complete response; the ORR was 100% for patients with indolent lymphoma (n = 27) and 57% for those with aggressive histology lymphoma (n = 21).",Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154915/),%,24,202922,DB00073,Rituximab
,27154915,ORR,"Among patients receiving the MTD (n = 38), the overall response rate (ORR) was 84% (n = 32), including 24% (n = 9) with complete response; the ORR was 100% for patients with indolent lymphoma (n = 27) and 57% for those with aggressive histology lymphoma (n = 21).",Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154915/),,100,202923,DB00073,Rituximab
,27154915,ORR,"Among patients receiving the MTD (n = 38), the overall response rate (ORR) was 84% (n = 32), including 24% (n = 9) with complete response; the ORR was 100% for patients with indolent lymphoma (n = 27) and 57% for those with aggressive histology lymphoma (n = 21).",Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154915/),,57,202924,DB00073,Rituximab
,20140617,t (1/2),The intermediate t (1/2) (40 min) was considered the pharmacologically relevant (beta elimination) t (1/2) since the initial phases accounted for 99% of the AUC.,Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20140617/),min,40,203731,DB00073,Rituximab
,16289160,half-life,The half-life of the total amount of rituximab in the two compartments was calculated to be 4.7 days.,The pharmacokinetics of rituximab following an intravitreal injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16289160/),d,4.7,204342,DB00073,Rituximab
,16289160,clearance from the aqueous humor,Fitting the data to a two-compartment model yielded a clearance from the aqueous humor of 1.2 microl/min.,The pharmacokinetics of rituximab following an intravitreal injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16289160/),[μl] / [min],1.2,204343,DB00073,Rituximab
,20555126,Trough levels,"Trough levels of 4 patients on three-monthly schedule maintenance therapy remained constant, with a median concentration of 6 mu g/mL (range 0.5-11.7 microg/mL).",Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20555126/),[g·mu] / [ml],6,204913,DB00073,Rituximab
,20555126,elimination half-life at steady state,"The elimination half-life at steady state of rituximab in all patients was estimated to be 19.2 (+/- 15.2%) days with a between-subject variability of 54%, indicating wide variability.",Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20555126/),d,19.2,204914,DB00073,Rituximab
,27233802,terminal half-life,The terminal half-life in cancer subjects was estimated to be approximately 26 h.,Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27233802/),h,26,205732,DB00073,Rituximab
,27233802,accumulation ratio,Venetoclax showed minimal accumulation with accumulation ratio of 1.30-1.44.,Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27233802/),,1.30-1.44,205733,DB00073,Rituximab
≥,32144134,MTD,The MTD for utomilumab in combination with rituximab was not reached and estimated to be ≥10 mg/kg every 4 weeks.,"First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32144134/),[mg] / [kg],10,206485,DB00073,Rituximab
,32144134,objective response rate,"The objective response rate was 21.2% (95% CI, 12.1%-33.0%) in all patients with NHL, including four complete and 10 partial responses.","First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32144134/),%,21.2,206486,DB00073,Rituximab
,26687959,serum peak concentration,"After treatment with 8 mg/kg of dulanermin, in six patients the mean serum peak concentration was 80 μg/mL, dropping below the minimum detectable concentration (2 ng/mL) within 24 h after the dose.",Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26687959/),[μg] / [ml],80,209808,DB00073,Rituximab
,26687959,minimum detectable concentration,"After treatment with 8 mg/kg of dulanermin, in six patients the mean serum peak concentration was 80 μg/mL, dropping below the minimum detectable concentration (2 ng/mL) within 24 h after the dose.",Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26687959/),[ng] / [ml],2,209809,DB00073,Rituximab
,26687959,steady state peak,"The mean steady state peak and trough concentrations of rituximab were 461 μg/mL (SD 97.5) and 303 μg/mL (92.8), respectively.",Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26687959/),[μg] / [ml],461,209810,DB00073,Rituximab
,26687959,trough concentrations,"The mean steady state peak and trough concentrations of rituximab were 461 μg/mL (SD 97.5) and 303 μg/mL (92.8), respectively.",Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26687959/),[μg] / [ml],303,209811,DB00073,Rituximab
,27199517,T1/2,"At the 375 mg/m(2) dose, the T1/2 was 122.5±46.7 h vs.",Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27199517/),h,122.5,210100,DB00073,Rituximab
,27199517,Cmax,"197.0±75.0 h, respectively, and the Cmax was 200.6±20.2 g/mL vs. 339.1±71.0 g/mL, respectively.",Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27199517/),[g] / [ml],200.6,210101,DB00073,Rituximab
,27199517,Cmax,"197.0±75.0 h, respectively, and the Cmax was 200.6±20.2 g/mL vs. 339.1±71.0 g/mL, respectively.",Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27199517/),[g] / [ml],339.1,210102,DB00073,Rituximab
,31724191,overall response rate,The overall response rate was 44.71% in BCD-020 arm and 41.89% in comparator arm.,Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31724191/),%,44.71,212640,DB00073,Rituximab
,31724191,overall response rate,The overall response rate was 44.71% in BCD-020 arm and 41.89% in comparator arm.,Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31724191/),%,41.89,212641,DB00073,Rituximab
,33256806,half-life,"In cynomolgus monkeys, hAB21 has a half-life of 5.3 days at 10 mg/kg and complete target occupancy with no hematological toxicity or adverse findings at doses up to 30 mg/kg.",Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33256806/),d,5.3,213667,DB00073,Rituximab
,21624007,time to maximum blood concentration,"The maximum drug concentration and area under the blood concentration-time curve for bendamustine increased dose dependently, with time to maximum blood concentration = 1.0 h in both cohorts; these pharmacokinetic data were similar to those reported previously for single-agent bendamustine in patients with indolent B-NHL.",Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21624007/),h,1.0,219321,DB00073,Rituximab
exceed,23716541,trough level,"Although rituximab trough levels increased progressively with each cycle, only by cycle 4 did the median trough level exceed 10 ug/mL.",Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23716541/),[ug] / [ml],10,220088,DB00073,Rituximab
,23716541,half-life,"The median half-life of rituximab during cycle 1 was 27 hours, compared to 199 hours during cycle 4 (P<0.0001).",Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23716541/),h,27,220089,DB00073,Rituximab
,23716541,half-life,"The median half-life of rituximab during cycle 1 was 27 hours, compared to 199 hours during cycle 4 (P<0.0001).",Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23716541/),h,199,220090,DB00073,Rituximab
,21699456,AUC,"There was substantial inter-individual variability in MTX AUC (median: 795.5 µM*h/L, range 44.8-8326.44).",Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21699456/),[h·μM] / [l],795.5,224886,DB00073,Rituximab
,23802738,overall response rate,The overall response rate was 96% (69/72) including complete response (CR) in 65 (90%) and unconfirmed CR in 2 (3%).,"Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802738/),%,96,226475,DB00073,Rituximab
,16306856,elimination half-life,"Rituximab disposition was characterized by a 2-exponential decay, with a long elimination half-life of approximately 3 weeks (range, 248-859 hours).",Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16306856/),weeks,3,232237,DB00073,Rituximab
,16306856,total systemic clearance,The total systemic clearance ranged between 3.1 and 11.9 mL/hr/m.,Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16306856/),[ml] / [h·m],3.1 and 11.9,232238,DB00073,Rituximab
,9653494,elimination half-life (T1/2),"A pharmacokinetic analysis showed that the elimination half-life (T1/2) of IDEC-C2B8 was 445 +/- 361 hours, and that the serum antibody levels increased in parallel with the course of infusions, and in most patients was still measurable at three months.","Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653494/),h,445,233408,DB00073,Rituximab
,33914391,AUC0-24 h threshold,"That led to an AUC0-24 h threshold of 89 mg*h/L associated with excellent performances (AUC ROC = 0.828, Sen = 75%, Spe = 100%, P = 0.0001).",Towards therapeutic drug monitoring of mycophenolic acid in mucous membrane pemphigoid: A retrospective single-centre study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33914391/),[h·mg] / [l],89,235604,DB00073,Rituximab
,33914391,AUC0-24 h,Therapeutic drug monitoring can be proposed with an AUC0-24 h threshold of 89 mg*h/L.,Towards therapeutic drug monitoring of mycophenolic acid in mucous membrane pemphigoid: A retrospective single-centre study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33914391/),[h·mg] / [l],89,235605,DB00073,Rituximab
,28230269,volume of distribution of central compartment,"The volume of distribution of central compartment and clearance of rituximab were estimated at 4.7 l and 0.56 l day-1 , respectively.",Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28230269/),l,4.7,240680,DB00073,Rituximab
,28230269,clearance,"The volume of distribution of central compartment and clearance of rituximab were estimated at 4.7 l and 0.56 l day-1 , respectively.",Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28230269/),[l] / [d],0.56,240681,DB00073,Rituximab
,28230269,Distribution,"Distribution and elimination half-lives were 0.9 days and 17.3 days, respectively.",Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28230269/),d,0.9,240682,DB00073,Rituximab
,28230269,elimination half-lives,"Distribution and elimination half-lives were 0.9 days and 17.3 days, respectively.",Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28230269/),d,17.3,240683,DB00073,Rituximab
,22438256,best overall response,Eight patients received maintenance; best overall response was 32% (6 partial responses/1 complete response).,A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22438256/),%,32,241407,DB00073,Rituximab
,22335424,overall response rate,"The overall response rate was 80% (8/10; 95% CI, 44-98%).",Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22335424/),%,80,251756,DB00073,Rituximab
,24297867,clearances,"The similar improvements of outcome in young patients were associated with similar rituximab clearances in young males and females (9.89 vs 10.38 mL/h; P = .238), whereas the greater benefit for elderly females was associated with a slower rituximab clearance (8.47 vs 10.59 mL/h; P = .005) and hence higher serum levels and longer exposure times, attributable to an age-dependent (P = .004) decrease of rituximab clearance in females but not males.",Suboptimal dosing of rituximab in male and female patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24297867/),[ml] / [h],9.89,252413,DB00073,Rituximab
,24297867,clearances,"The similar improvements of outcome in young patients were associated with similar rituximab clearances in young males and females (9.89 vs 10.38 mL/h; P = .238), whereas the greater benefit for elderly females was associated with a slower rituximab clearance (8.47 vs 10.59 mL/h; P = .005) and hence higher serum levels and longer exposure times, attributable to an age-dependent (P = .004) decrease of rituximab clearance in females but not males.",Suboptimal dosing of rituximab in male and female patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24297867/),[ml] / [h],10.38,252414,DB00073,Rituximab
,24297867,clearance,"The similar improvements of outcome in young patients were associated with similar rituximab clearances in young males and females (9.89 vs 10.38 mL/h; P = .238), whereas the greater benefit for elderly females was associated with a slower rituximab clearance (8.47 vs 10.59 mL/h; P = .005) and hence higher serum levels and longer exposure times, attributable to an age-dependent (P = .004) decrease of rituximab clearance in females but not males.",Suboptimal dosing of rituximab in male and female patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24297867/),[ml] / [h],8.47,252415,DB00073,Rituximab
,24297867,clearance,"The similar improvements of outcome in young patients were associated with similar rituximab clearances in young males and females (9.89 vs 10.38 mL/h; P = .238), whereas the greater benefit for elderly females was associated with a slower rituximab clearance (8.47 vs 10.59 mL/h; P = .005) and hence higher serum levels and longer exposure times, attributable to an age-dependent (P = .004) decrease of rituximab clearance in females but not males.",Suboptimal dosing of rituximab in male and female patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24297867/),[ml] / [h],10.59,252416,DB00073,Rituximab
,24521993,Ctrough,"Geometric mean Ctrough was 83·13 μg/mL in the intravenous group and 134·58 μg/mL in the subcutaneous group (ratio 1·62, 90% CI 1·36-1·94), showing non-inferiority of subcutaneous rituximab.",Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521993/),[μg] / [ml],83·13,253189,DB00073,Rituximab
,24521993,Ctrough,"Geometric mean Ctrough was 83·13 μg/mL in the intravenous group and 134·58 μg/mL in the subcutaneous group (ratio 1·62, 90% CI 1·36-1·94), showing non-inferiority of subcutaneous rituximab.",Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521993/),[μg] / [ml],134·58,253190,DB00073,Rituximab
,12393404,terminal half-life,"Pharmacokinetic analysis suggests that drug clearance from the CSF is biphasic, with a terminal half-life of 4.96 hours.",Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12393404/),h,4.96,257829,DB00073,Rituximab
,34251329,concentration,"In all ADA-positive patients, RTX concentrations were undetectable in contrast to ADA-negative patients (median RTX concentration 3.1 μg/ml; IQR 0.57-12.0; p<0.001).",Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34251329/),[μg] / [ml],3.,259419,DB00073,Rituximab
<,17470451,time to progression,Rituximab-refractory patients (no response or a response with time to progression <6 months) were excluded.,"A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470451/),month,6,263274,DB00073,Rituximab
,17470451,overall response rate,"The overall response rate at the recommended phase II dose of galiximab (500 mg/m(2)) was 66%: 19% complete response, 14% unconfirmed complete response, and 33% partial response.","A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470451/),%,66,263275,DB00073,Rituximab
,17470451,overall response rate,"The overall response rate at the recommended phase II dose of galiximab (500 mg/m(2)) was 66%: 19% complete response, 14% unconfirmed complete response, and 33% partial response.","A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470451/),%,19,263276,DB00073,Rituximab
,17470451,overall response rate,"The overall response rate at the recommended phase II dose of galiximab (500 mg/m(2)) was 66%: 19% complete response, 14% unconfirmed complete response, and 33% partial response.","A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470451/),%,14,263277,DB00073,Rituximab
,17470451,overall response rate,"The overall response rate at the recommended phase II dose of galiximab (500 mg/m(2)) was 66%: 19% complete response, 14% unconfirmed complete response, and 33% partial response.","A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470451/),%,33,263278,DB00073,Rituximab
,17470451,progression free survival,The median progression free survival was 12.1 months.,"A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470451/),month,12.1,263279,DB00073,Rituximab
,27010483,progression-free survival,"Median progression-free survival, overall survival and duration of response were 3·9 [80% CI: 3·22-3·98], 9·0 [80% CI: 6·47-13·67] and 8·6 (range: 0-18) months, respectively.","A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27010483/),month,3·9,265516,DB00073,Rituximab
,27010483,overall survival,"Median progression-free survival, overall survival and duration of response were 3·9 [80% CI: 3·22-3·98], 9·0 [80% CI: 6·47-13·67] and 8·6 (range: 0-18) months, respectively.","A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27010483/),month,9·0,265517,DB00073,Rituximab
,27010483,overall survival,"Median progression-free survival, overall survival and duration of response were 3·9 [80% CI: 3·22-3·98], 9·0 [80% CI: 6·47-13·67] and 8·6 (range: 0-18) months, respectively.","A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27010483/),month,8·6,265518,DB00073,Rituximab
,27010483,duration of response,"Median progression-free survival, overall survival and duration of response were 3·9 [80% CI: 3·22-3·98], 9·0 [80% CI: 6·47-13·67] and 8·6 (range: 0-18) months, respectively.","A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27010483/),month,9·0,265519,DB00073,Rituximab
,27010483,duration of response,"Median progression-free survival, overall survival and duration of response were 3·9 [80% CI: 3·22-3·98], 9·0 [80% CI: 6·47-13·67] and 8·6 (range: 0-18) months, respectively.","A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27010483/),month,8·6,265520,DB00073,Rituximab
,22337718,Total clearance,Total clearance was 9.43 mL/h and Vd(ss) was 9.61 l.,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],9.43,266008,DB00073,Rituximab
,22337718,Vd(ss),Total clearance was 9.43 mL/h and Vd(ss) was 9.61 l.,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),l,9.61,266009,DB00073,Rituximab
,22337718,clearance,Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],8.21,266010,DB00073,Rituximab
,22337718,clearance,Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],12.68,266011,DB00073,Rituximab
,22337718,t(1/2β),Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),d,30.7,266012,DB00073,Rituximab
,22337718,t(1/2β),Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),d,24.7,266013,DB00073,Rituximab
,22511498,complete remission,"Significantly higher complete remission rates were observed in female patients (86 vs. 47%; Odds Ratio 6.8, 95% CI: 1.12; 41.82; P=0.05).","Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511498/),,86,269684,DB00073,Rituximab
,22511498,complete remission,"Significantly higher complete remission rates were observed in female patients (86 vs. 47%; Odds Ratio 6.8, 95% CI: 1.12; 41.82; P=0.05).","Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511498/),,47,269685,DB00073,Rituximab
,22511498,area under the curve,"Rituximab pharmacokinetic analysis showed a high variability ranging over almost 1 order of magnitude at maintenance cycle 1 (area under the curve 1,540-12,025 g/L*days).","Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511498/),[g] / [d·l],"1,540-12,025",269686,DB00073,Rituximab
below,22511498,C(trough),"A decline in rituximab C(trough) below 25,000 ng/mL was observed 9.5 to 62 months before clinical relapse (P=0.008).","Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511498/),[ng] / [ml],"25,000",269687,DB00073,Rituximab
,11418315,overall response rate,"In a prospectively defined 90 patient interim analysis, the overall response rate was 80% for Zevalin vs. 44% for rituximab.","Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418315/),%,80,272468,DB00073,Rituximab
,11418315,overall response rate,"In a prospectively defined 90 patient interim analysis, the overall response rate was 80% for Zevalin vs. 44% for rituximab.","Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418315/),%,44,272469,DB00073,Rituximab
,11418315,radiation absorbed doses,"For all patients with Zevalin dosimetry data (N=72), radiation absorbed doses were estimated to be below the protocol-defined upper limits of 300 cGy to red marrow and 2000 cGy to normal organs.","Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418315/),c,300,272470,DB00073,Rituximab
,11418315,radiation absorbed doses,"For all patients with Zevalin dosimetry data (N=72), radiation absorbed doses were estimated to be below the protocol-defined upper limits of 300 cGy to red marrow and 2000 cGy to normal organs.","Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418315/),,2000,272471,DB00073,Rituximab
,11418315,radiation absorbed doses,"The median estimated radiation absorbed doses were 71 cGy to red marrow (range: 18-221 cGy), 216 cGy to lungs (94-457 cGy), 532 cGy to liver (range: 234-1856 cGy), 848 cGy to spleen (range: 76-1902 cGy), 15 cGy to kidneys (0.27-76 cGy) and 1484 cGy to tumor (range: 61-24274 cGy).","Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418315/),cgy,71,272472,DB00073,Rituximab
,11418315,radiation absorbed doses,"The median estimated radiation absorbed doses were 71 cGy to red marrow (range: 18-221 cGy), 216 cGy to lungs (94-457 cGy), 532 cGy to liver (range: 234-1856 cGy), 848 cGy to spleen (range: 76-1902 cGy), 15 cGy to kidneys (0.27-76 cGy) and 1484 cGy to tumor (range: 61-24274 cGy).","Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418315/),,18,272473,DB00073,Rituximab
,11418315,radiation absorbed doses,"The median estimated radiation absorbed doses were 71 cGy to red marrow (range: 18-221 cGy), 216 cGy to lungs (94-457 cGy), 532 cGy to liver (range: 234-1856 cGy), 848 cGy to spleen (range: 76-1902 cGy), 15 cGy to kidneys (0.27-76 cGy) and 1484 cGy to tumor (range: 61-24274 cGy).","Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418315/),,216,272474,DB00073,Rituximab
,11418315,radiation absorbed doses,"The median estimated radiation absorbed doses were 71 cGy to red marrow (range: 18-221 cGy), 216 cGy to lungs (94-457 cGy), 532 cGy to liver (range: 234-1856 cGy), 848 cGy to spleen (range: 76-1902 cGy), 15 cGy to kidneys (0.27-76 cGy) and 1484 cGy to tumor (range: 61-24274 cGy).","Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418315/),,532,272475,DB00073,Rituximab
,11418315,radiation absorbed doses,"The median estimated radiation absorbed doses were 71 cGy to red marrow (range: 18-221 cGy), 216 cGy to lungs (94-457 cGy), 532 cGy to liver (range: 234-1856 cGy), 848 cGy to spleen (range: 76-1902 cGy), 15 cGy to kidneys (0.27-76 cGy) and 1484 cGy to tumor (range: 61-24274 cGy).","Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418315/),cgy,848,272476,DB00073,Rituximab
,11418315,radiation absorbed doses,"The median estimated radiation absorbed doses were 71 cGy to red marrow (range: 18-221 cGy), 216 cGy to lungs (94-457 cGy), 532 cGy to liver (range: 234-1856 cGy), 848 cGy to spleen (range: 76-1902 cGy), 15 cGy to kidneys (0.27-76 cGy) and 1484 cGy to tumor (range: 61-24274 cGy).","Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418315/),c,15,272477,DB00073,Rituximab
,11418315,radiation absorbed doses,"The median estimated radiation absorbed doses were 71 cGy to red marrow (range: 18-221 cGy), 216 cGy to lungs (94-457 cGy), 532 cGy to liver (range: 234-1856 cGy), 848 cGy to spleen (range: 76-1902 cGy), 15 cGy to kidneys (0.27-76 cGy) and 1484 cGy to tumor (range: 61-24274 cGy).","Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418315/),c,1484,272478,DB00073,Rituximab
